Showing results (161-170 of 186) with videos related to

Sort By:
Pageof 19
Eclinicalmedicine|November 8, 2024
Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trialMaria Pilar Ruiz Seco, José Ramón Paño Pardo, Christian Schoergenhofer, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 25, 2002
The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal modelsDaisy W J van der Schaft, Ruud P M Dings, Quido G de Lussanet, et al.
European Journal of Medicinal Chemistry|December 3, 2014
Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[(18)F]fluoroethylazide, and in vivo evaluationTilman Läppchen, Ruud P M Dings, Raffaella Rossin, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|August 18, 2024
Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohortMarjolein F Lansbergen, Mark P G Dings, Paul Manoukian, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 4, 2006
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumorsAnita E M Dirkx, Mirjam G A oude Egbrink, Karolien Castermans, et al.
Brain : a Journal of Neurology|February 13, 2018
Brain tissue plasticity: protein synthesis rates of the human brainJoey S J Smeets, Astrid M H Horstman, Olaf E M G Schijns, et al.
Med (New York, N.Y.)|February 12, 2025
KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancerMarjolein F Lansbergen, Mark P G Dings, Jan Koster, et al.
Cancers|September 10, 2020
CCAAT/Enhancer-Binding Protein Delta (C/EBPδ): A Previously Unrecognized Tumor Suppressor that Limits the Oncogenic Potential of Pancreatic Ductal Adenocarcinoma CellsLeonie Hartl, JanWillem Duitman, Hella L Aberson, et al.
Epilepsia|December 5, 2025
Pseudoaneurysms as a complication of stereoelectroencephalography: Case series and clinical recommendationsYoussra El Khou, Rick H G J van Lanen, G Louis Wagner, et al.
BMJ Open|July 5, 2023
Resective Epilepsy Surgery, QUality of life and Economic evaluation (RESQUE): the change in quality of life after resective epilepsy surgery-protocol for a multicentre, prospective cohort studyJulia T F Kellenaers, Kim Rijkers, Ghislaine A P G van Mastrigt, et al.
Pageof 19